Kezar Life Sciences Inc (NASDAQ: KZR) stock jumped 2.93% on Monday to $0.89 against a previous-day closing price of $0.86. With 0.81 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.51 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.9070 whereas the lowest price it dropped to was $0.8230. The 52-week range on KZR shows that it touched its highest point at $7.89 and its lowest point at $0.67 during that stretch. It currently has a 1-year price target of $12.50. Beta for the stock currently stands at 0.44.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KZR was up-trending over the past week, with a rise of 21.68%, but this was down by -7.25% over a month. Three-month performance dropped to -36.78% while six-month performance fell -70.88%. The stock lost -88.06% in the past year, while it has lost -87.43% so far this year. A look at the trailing 12-month EPS for KZR yields -1.21 with Next year EPS estimates of -1.11. For the next quarter, that number is -0.36. This implies an EPS growth rate of -33.26% for this year and 17.88% for next year.
Float and Shares Shorts:
At present, 68.49 million KZR shares are outstanding with a float of 58.23 million shares on hand for trading. On Oct 30, 2023, short shares totaled 2.2 million, which was 3.02% higher than short shares on Sep 28, 2023. In addition to Mr. John Franklin Fowler as the firm’s Co-Founder & Director, Dr. Christopher J. Kirk Ph.D. serves as its Co-Founder, CEO & Director.
Through their ownership of 86.69% of KZR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 48.83% of KZR, in contrast to 19.39% held by mutual funds. Shares owned by individuals account for 18.41%. As the largest shareholder in KZR with 9.86% of the stake, Suvretta Capital Management LLC holds 7,167,591 shares worth 7,167,591. A second-largest stockholder of KZR, Avidity Partners Management LP, holds 6,011,100 shares, controlling over 8.27% of the firm’s shares. Prosight Management LP is the third largest shareholder in KZR, holding 4,770,799 shares or 6.56% stake. With a 2.65% stake in KZR, the Biotech Growth Trust Plc is the largest stakeholder. A total of 1,927,000 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.58% of KZR stock, is the second-largest Mutual Fund holder. It holds 1,877,555 shares valued at 1.35 million. iShares Russell 2000 ETF holds 2.24% of the stake in KZR, owning 1,630,693 shares worth 1.18 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KZR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With KZR analysts setting a high price target of $20.00 and a low target of $2.00, the average target price over the next 12 months is $12.50. Based on these targets, KZR could surge 2147.19% to reach the target high and rise by 124.72% to reach the target low. Reaching the average price target will result in a growth of 1304.49% from current levels.
Summary of Insider Activity:
Insiders traded KZR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has risen to 18 over the past year. The total number of shares bought during that period was 48,950 while 4,008,747 shares were sold.